Pfizer Canada Invests $750,000 in Q-CROC
PHILADELPHIA (Pennsylvania), June 3, 2019 – Pfizer Canada is proud to announce a $750,000 contribution to Q-CROC to address numerous health needs identified by the scientific community, industry partners, patients and the government.
Pfizer’s financial support will assist Q-CROC in its ongoing efforts to create a group of specialist researchers and develop initiatives aimed at raising awareness about clinical research among the general public and healthcare professionals. The objective is to offer patients in Quebec greater opportunities to take part in clinical trials and foster cooperation among hospitals province-wide.
John Helou, President of Pfizer Canada:
“Pfizer is committed to developing and providing treatments that significantly improve patients’ lives. We work with healthcare professionals, governments, university scientists and local communities to promote access to medicines. We are proud of our collaboration with Q-CROC through this $750,000 contribution that will help support clinical research in oncology in Quebec and facilitate access to clinical trials on investigational therapies for cancer patients in the province.”
Lucie D’Amours, Interim Executive Director, Q-CROC:
“The creation of specialist researcher groups is essential for the implementation of an efficient system that will make more clinical studies available to cancer patients in Quebec and facilitate their access to oncology clinical trials. Ultimately, it is the patients who will benefit tremendously from such collaborative endeavours between clinical research stakeholders.”
Pierre Fitzgibbon, Minister of Economy and Innovation:
“The Québec government applauds Pfizer Canada’s contribution, which will further stimulate collaboration between Québec doctors and researchers. I am convinced that this will lead to great strides for Québec’s life sciences industry, enhancing the industry’s reputation while significantly improving the quality of life of numerous cancer patients. We hope to generate more than $4 billion in private investments by 2022 to help foster rapid growth in Québec’s life sciences industry.”
About Pfizer Canada
Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world’s leading biopharmaceutical companies. Our diversified healthcare portfolio includes some of the world’s best known and most prescribed medicines, vaccines and consumer health products. In 2017, Pfizer invested US$7.65 billion globally for the development of safe and effective drugs and participated in over 180 new collaborative research and development projects. The Canadian headquarters of the Pfizer Biopharmaceutical Group (PBG) is in Kirkland, Quebec. To learn more about Pfizer Canada, visit pfizer.ca or you can follow us on LinkedIn, Facebook, Twitter or YouTube.
About the Quebec – Clinical Research Organization in Cancer
The Quebec – Clinical Research Organization in Cancer coordinates a network bringing together 17 of the most active healthcare institutions in clinical research in oncology in the province. It includes over 250 investigators and over 500 research professionals. Fourteen Q-CROC liaison agents support the clinical field research teams. Q-CROC offers activities aimed at supporting clinical research quality and compliance in Quebec and is making every effort to raise awareness concerning the importance of clinical research for the Quebec population and healthcare professionals. For more information, follow us on Twitter or LinkedIn.
For more information:
Pfizer Canada Media Line: 1-866-9Pfizer (1 866 973-4937)
CorporateAffairsCanada@pfizer.com
Amélie Bérubé Project Manager, Communication Q-CROC 418 781-0500 aberube@qcroc.ca
